Multidisciplinary | Home

Malaysia
Search
Sign In

Multidisciplinary Search

Multidisciplinary

Multidisciplinary

Home News Diseases Conferences Special Reports Multimedia

Navigating the unknowns in COVID-19 the ACP way

Pearl Toh, 33 minutes ago

In the face of the COVID-19 pandemic which has taken the world by storm, the lack of approved treatments targeted towards coronavirus has left physicians worldwide grappling with the situation. To help them navigate the black box of COVID-19 management, the ACP* has released a behemoth 28-chapter guide to arm physicians in the virus-infested battle field.

Radiation risk awareness lacking in patients, some physicians

Stephen Padilla, 7 hours ago

Awareness of medical radiation risk needs improvement among patients and their parents or caregivers, according to the results of a Singapore study, which also highlights a mismatch between caregiver expectations and the actual procedure of radiation risk disclosure.

Cardiovascular risk burden tied to neurodegeneration, cognitive decline

8 hours ago

Higher cardiovascular risk burden correlates with neurodegeneration and vascular lesions in the brain and appears to be a predictor of decline in episodic memory, working memory, and perceptual speed, a study has shown.

Activated vitamin D significantly improves bone mineral density in osteoporotic patients

21 May 2020

At the 13th Annual Scientific Meeting of the Malaysian Osteoporosis Society (MOS), Dr Chan Siew Pheng discussed the role of alfacalcidol (One-Alpha®) in the treatment of osteoporosis (OP) and presented several patient profiles where alfacalcidol exhibited efficacy in increasing bone mineral density (BMD).

Empagliflozin’s cardiovascular benefits lead the change in T2D treatment paradigm

11 May 2020

This second issue revisits the impact EMPA-REG OUTCOME had on clinical practice and helps readers discover how it gives life back to patients through its cardiovascular indication. Learn how it was approved and the possible mechanisms for its cardiovascular benefits.

Sacubitril/valsartan prevents hospital readmission in a patient with HF following AMI

05 May 2020

Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.¹ Several studies suggest a rising prevalence of HF, which could be attributed to the ageing of the population, along with improved HF survival owing to the tremendous advancement in HF therapy.^2–4 In this case study, Dato’ Dr Ahmad Murtazam shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following acute myocardial infarction (AMI) and multiple hospitalisations.

Ticagrelor benefits in TWILIGHT hold up in diabetes

Roshini Claire Anthony, 23 Apr 2020

Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.

Ticagrelor monotherapy outshines DAPT after complex PCI

Audrey Abella, 23 Apr 2020

Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.

TICO backs ticagrelor alone in ACS post-PCI

Pearl Toh, 23 Apr 2020

Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.

Subgroup findings boost elagolix benefit in uterine fibroid-induced menstrual bleeding

Audrey Abella, 29 May 2020

The addition of the oral GnRH* antagonist elagolix to hormonal add-back therapy (E2/NETA**) reduces menstrual blood loss (MBL) in women with heavy menstrual bleeding (HMB) associated with uterine fibroids (UF) and comorbid adenomyosis, with the extension phase showing benefits beyond 6 months, according to data presented at ACOG 2020.

Does a single round of 3HP work for PLWH on ART?

Elvira Manzano, 28 May 2020

A once-weekly tuberculosis (TB) prevention regimen of isoniazid 900 mg and rifapentine 900 mg given for 3 months (3HP) resulted in higher treatment completion rates vs isoniazid daily for 6 months (6H) in patients with HIV receiving antiretroviral therapy (ART), a study released at CROI 2020 has shown.

Vaginal cleansing prophylaxis reduces SSIs after Caesarean delivery

Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates.

GU symptoms down, sexual satisfaction up with new vaginal contraceptive gel

Audrey Abella, 26 May 2020

A novel, investigational vaginal pH regulator (VPR) – a nonhormonal, water-based, petroleum-free contraceptive vaginal gel – improved genitourinary (GU) side effects and sexual satisfaction in women who are at risk of pregnancy but are not aiming to conceive, interim findings from the phase III AMPOWER* trial show.

Contraception with LNG-IUD still effective up to 6 years

Pearl Toh, 21 May 2020

A levonorgestrel (LNG)-releasing intrauterine device (IUD) maintains high contraceptive efficacy up to 6 years, which is beyond the 5-year period it is currently approved for, according to data from the Mirena Extension Trial (MET) released during the ACOG 2020 Meeting.

Olaparib-bevacizumab PFS benefit in ovarian cancer greatest following upfront surgery

Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!